Connor, Clark & Lunn Investment Management (CC&L)’s Axsome Therapeutics AXSM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.9M	Sell	97,698 -37,094	-28%	-$8.04M	0.05%	330
2026 Q1	$22.8M	Sell	134,792 -53,466	-28%	-$9.24M	0.05%	297
2025 Q4	$34.4M	Sell	188,258 -20,811	-10%	-$2.91M	0.09%	185
2025 Q3	$25.4M	Sell	209,069 -15,652	-7%	-$1.76M	0.08%	222
2025 Q2	$23.5M	Buy	224,721 +48,779	+28%	+$5.17M	0.08%	213
2025 Q1	$20.5M	Buy	175,942 +102,445	+139%	+$11.7M	0.09%	186
2024 Q4	$6.22M	Buy	+73,497	New	+$6.76M	0.03%	429
2024 Q1	–	Sell	-14,339	Closed	-$1.14M	–	1521
2023 Q4	$1.14M	Buy	+14,339	New	+$959K	0.01%	825
2022 Q2	–	Sell	-9,195	Closed	-$381K	–	1038
2022 Q1	$381K	Buy	+9,195	New	+$285K	﹤0.01%	831

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s AXSM Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Axsome Therapeutics (AXSM) stake by 28% in Q2 2026, selling an estimated $8.04M and leaving 97,698 shares worth $23.9M. The position accounts for 0.05% of the portfolio, ranked #330.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in AXSM in Q1 2022 and has held it in 9 quarters since. The position peaked at $34.4M in Q4 2025. 504 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 97,698 shares of Axsome Therapeutics worth $23.9M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 37,094 Axsome Therapeutics shares in Q2 2026, an estimated $8.04M.
Axsome Therapeutics made up 0.05% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #330 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Axsome Therapeutics in Q1 2022 and has held it in 9 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Axsome Therapeutics position peaked at $34.4M in Q4 2025.
504 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.